AirBnB ABNB stock analysis 25SEP23

The FDA approved a recombinant ADAMTS13 protein product (Adzynma) as a prophylactic or on-demand enzyme replacement therapy for patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Can Ken Mul­vany save Benev­o­len­tAI? About a decade ago, Mul­vany helped found the com­pa­ny as part of the first gen­er­a­tion of AI-fo­cused biotech star­tups. It